Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer

BMC Cancer. 2023 Mar 9;23(1):224. doi: 10.1186/s12885-023-10631-w.

Abstract

Purpose: A previous meta-analysis examining the relationship between statin use and breast cancer reported that the inhibitory effect of statins on breast cancer may be more pronounced in early-stage cases. In this study, we aimed to investigate the effects of hyperlipidemia treatment at the time of breast cancer diagnosis and to examine its correlation with metastasis to axillary lymph nodes among patients with so-called cT1 breast cancer whose primary lesion was 2 cm or less and was pathologically evaluated by sentinel lymph node biopsy or axillary lymph node dissection. We also investigated the effects of hyperlipidemic drugs on the prognosis of patients with early-stage breast cancer.

Methods: After excluding cases that did not meet the criteria, we analyzed data from 719 patients who were diagnosed with breast cancer, with a primary lesion of 2 cm or less identified by preoperative imaging, and who underwent surgery without preoperative chemotherapy.

Results: Regarding hyperlipidemia drugs, no correlation was found between statin use and lymph node metastasis (p = 0.226), although a correlation was found between lipophilic statin use and lymph node metastasis (p = 0.042). Also, the disease-free survival periods were prolonged following treatment of hyperlipidemia (p = 0.047, hazard ratio: 0.399) and statin administration (p = 0.028, hazard ratio: 0.328).

Conclusion: In cT1 breast cancer, the results suggest that oral statin therapy may contribute to favorable outcomes.

Keywords: axillary lymph node; breast cancer; hyperlipidemia; prognosis; statin.

MeSH terms

  • Axilla / pathology
  • Breast Neoplasms* / pathology
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Lymph Node Excision / methods
  • Lymph Nodes / pathology
  • Lymphatic Metastasis / pathology
  • Sentinel Lymph Node Biopsy / methods

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors